title: [The synergistic effects of paclitaxel and gemcitabine on prostate cancer cell line PC-3].
abstract: OBJECTIVE
  To observe the synergistic effects of paclitaxel and gemcitabine on prostate cancer cell line PC-3 in vitro.
  
  
  METHODS
  Cell morphology, MTU, flow cytometer and immunocytochemical method were used to observe the effects of 10(-6), 10(-7), 10(-8) mol/L paclitaxel and 10(-7), 10(-8), 10(-9) mol/L gemcitabine on prostate cancer cell line PC-3 by single or synergistic administration for 48 hours in vitro.
  
  
  RESULTS
  Gemcitabine above 10(-8) mol/L enhanced the growth suppression [suppression ratio > or = (50.8 +/- 4.2)%, P < 0.05] and apoptosis [apoptosis ratio > or = (22.9 +/- 2.3)%, P < 0.05] and down-regulation of the expression of cyclin D1 [expression ratio < or = (9.6 +/- 1.6)%, P < 0.01] induced by paclitaxel above 10(-7) mol/L in PC-3 cells. Gemcitabine changed the ratio of G2/M cell arrest induced by paclitaxel from (70.3 +/- 9.7)% to (38.2 +/- 4.2)%, and reversed the G2/M arrest partially (P < 0.01).
  
  
  CONCLUSIONS
  Paclitaxel and gemcitabine can enhance the growth suppression and apoptosis induced by paclitaxel in a synergistic way. They show great potential in the treatment of androgen-independent carcinoma of the prostate.
authors.affiliation: Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China. sunming2003@163.com
authors.forename: Ming
authors.initials: M
authors.lastname: Sun
authors.forename: Yuru
authors.initials: Y
authors.lastname: Yang
authors.forename: Hong
authors.initials: H
authors.lastname: Li
authors.forename: Yirong
authors.initials: Y
authors.lastname: Chen
authors.forename: Zhiping
authors.initials: Z
authors.lastname: Wang
authors.forename: Yiping
authors.initials: Y
authors.lastname: Lu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Wei
authors.forename: Zhongjin
authors.initials: Z
authors.lastname: Yue
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D004357:Drug Synergism; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000473:pathology*; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D003841:Deoxycytidine; D017239:Paclitaxel; D000093542:Gemcitabine